Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 37.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,755 shares of the biopharmaceutical company’s stock after buying an additional 3,232 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Alnylam Pharmaceuticals were worth $2,766,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Capital Research Global Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after acquiring an additional 1,724,610 shares during the period. Capital World Investors increased its position in Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock worth $3,906,284,000 after purchasing an additional 92,101 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Alnylam Pharmaceuticals by 10.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 333,661 shares of the biopharmaceutical company’s stock worth $78,520,000 after purchasing an additional 32,272 shares during the period. First Trust Advisors LP boosted its holdings in shares of Alnylam Pharmaceuticals by 14.8% in the 4th quarter. First Trust Advisors LP now owns 327,782 shares of the biopharmaceutical company’s stock valued at $77,130,000 after purchasing an additional 42,211 shares during the last quarter. Finally, Alpha DNA Investment Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $710,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $234.56 on Monday. The stock has a market capitalization of $30.51 billion, a price-to-earnings ratio of -108.09 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company’s 50-day simple moving average is $249.14 and its 200-day simple moving average is $256.89. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several research reports. Bank of America increased their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Redburn Atlantic started coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a “buy” rating and a $353.00 price objective on the stock. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $315.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.